With rising numbers of COVID-19 infections and as the fight against the novel coronavirus continues, Novavax received $1.6 billion in federal funding to support the clinical development of the company’s vaccine candidate NVX‑CoV2373.

Regeneron Pharmaceuticals received a $450 million contract to manufacture and supply a two-antibody cocktail for the treatment and prevention of COVID-19 as part of Operation Warp Speed from the Biomedical Advanced Research and Development Authority (BARDA).

23andMe announced that the company was laying off about 100 employees as sales were down, reflecting a shrinking market for DNA test kits to consumers.

Abbott announced the next phase of partnership with the U.S. Department of Defense and researchers from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Network, one of the largest traumatic brain injury efforts of its kind.

The CEO of Platelet BioGenesis sees a future in the development of an on-demand platelet product made from stem cells.

Merck & Co. CEO Kenneth Frazier, speaking with the Economic Club of New York, joined a growing list of pharmaceutical chiefs in criticizing the role of middlemen in rising drug prices.

The U.S. Food and Drug Administration cleared Cleveland-based SPR Therapeutics’ SPRING endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation Systems for controlling pain.

The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome.

The U.S. FDA and Department of Defense launched a program to speed up the development of drugs that could be used by military personnel.

A filing with the U.S. Securities and Exchange Commission (SEC) indicates that the UK’s GlaxoSmithKline has a 13 percent stake in Spero Therapeutics, with 1,854,006 shares in the Massachusetts biotech company.